Interstitial Cystitis Market 2027

DelveInsight's 'Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Interstitial Cystitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Interstitial Cystitis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027


Interstitial Cystitis - Disease Understanding and Treatment Algorithm

Interstitial Cystitis (IC), also called as Painful Bladder Syndrome, is a chronic condition causing bladder pressure, bladder pain and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. Bladder is a hollow, muscular organ that stores urine. The bladder expands until it is full and then gives signals to the brain that it is time to urinate, communicating through the pelvic nerves. IC can be of two types: Non-Ulcerative and Ulcerative. However, IC was considered as a rare disease; this comes from a situation of underdiagnosis and misunderstandings about the nature of the IC. It was not until late 1970s, when researchers proved that the vast majority of patients with IC have no Hunner lesions.

The DelveInsight Interstitial Cystitis market report gives the thorough understanding of the Interstitial Cystitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Interstitial Cystitis in the US, Europe, and Japan.


Interstitial Cystitis Epidemiology

The Interstitial Cystitis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalent Population, Sex - Specific Prevalent Population, Total Diagnosed Prevalent population, Severity Specific Diagnosed Prevalence] scenario of Interstitial Cystitis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

DelveInsight's estimates suggest higher prevalence of Interstitial Cystitis in the United States with ~4,951,841 prevalent cases in 2016 and ~5,509,338 prevalent cases in 2027. Among the European countries, Germany had the highest prevalent population of Interstitial Cystitis with approximately 843,523 cases, followed by France in 2016. Furthermore, the estimates suggest higher prevalence of the disease among the females throughout the 7MM.


Interstitial Cystitis Drug Chapters

This segment of the Interstitial Cystitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The current therapeutic landscape of IC in the US can be divided into two major categories based on the route of administration: Oral Therapies and Intravesical Instillations. Among orally administered therapies, only Elmiron (Pentosan polysulfate sodium; Janssen Pharmaceuticals) is approved by U.S. Food and Drug Administration (FDA) for the treatment of IC. Detailed chapters of upcoming therapies such as Mirabegron (Astellas Pharma), ASP6294 (Astellas Pharma), LP-08 (Lipella Pharmaceuticals) and GRT6010 (Grünenthal) which are expected to launch during the forecast period [2018-2027] have also been covered in the report.


Interstitial Cystitis Market Outlook

The Interstitial Cystitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market size of Interstitial Cystitis in seven major markets is expected to reach USD 5372.71 billion by 2027 from USD 4659.58 billion in 2016. Among the three class therapies (Destructive Therapies, PhotoDynamic Therapies, and Topical Therapies), Destructive Therapy is the most prescribed, that led to highest market size, followed by Topical Therapies. The United States accounts for the largest market size of Interstitial Cystitis in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


Interstitial Cystitis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of Mirabegron (Astellas Pharma), ASP6294 (Astellas Pharma), LP-08 (Lipella Pharmaceuticals) and GRT6010 (Grünenthal) in the forecast period [2018-2027] will also create a positive impact on the Interstitial Cystitis market. Out of the above-mentioned therapies, LP-08 (Lipella Pharmaceuticals) holds the highest expectations.


Interstitial Cystitis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Interstitial Cystitis Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake


Interstitial Cystitis Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers


Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Interstitial Cystitis market
  • Organize sales and marketing efforts by identifying the best opportunities for Interstitial Cystitis market
  • To understand the future market competition in the Interstitial Cystitis market.

1. Key Insights

2. Interstitial Cystitis: Market Overview at a Glance

2.1. Total Market Share (%) Distribution of Interstitial Cystitis in 2016

2.2. Total Market Share (%) Distribution of Interstitial Cystitis in 2027

3. Interstitial Cystitis (IC): Disease Background and Overview

3.1. Introduction

3.2. Causes

3.3. Risk Factors

3.4. Signs and Symptoms

3.5. Pathophysiology

3.6. Biomarkers for patients with interstitial cystitis

3.7. Diagnosis

3.7.1. Consensus panel recommendations for the evaluation and diagnosis of patients with suspected IC/PBS

3.7.2. American Urology Association diagnosis guideline

3.7.3. Society of Interstitial Cystitis of Japan (SICJ) diagnosis guideline

4. Epidemiology and Patient Population

4.1. Population and Forecast Parameters

4.2. Key Findings

5. 7MM Total Prevalent Patient Population of Interstitial Cystitis

6. 7MM Total Diagnosed Prevalent Patient Population of Interstitial Cystitis

7. Country Wise-Epidemiology of Interstitial Cystitis

7.1. United States

7.1.1. Assumptions and Rationale

7.1.2. Total Prevalent Population of Interstitial Cystitis in the United States

7.1.3. Sex-Specific Prevalent Population of Interstitial Cystitis in the United States

7.1.4. Total Diagnosed Prevalence of Interstitial Cystitis in the United States

7.1.5. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States

7.2. EU5 Countries

7.2.1. Assumptions and Rationale

7.3. Germany

7.3.1. Total Prevalent Population of Interstitial Cystitis in Germany

7.3.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Germany

7.3.3. Total Diagnosed Prevalence of Interstitial Cystitis in Germany

7.3.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany

7.4. France

7.4.1. Total Prevalent Population of Interstitial Cystitis in France

7.4.2. Sex-Specific Prevalent Population of Interstitial Cystitis in France

7.4.3. Total Diagnosed Prevalence of Interstitial Cystitis in France

7.4.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in France

7.5. Italy

7.5.1. Total Prevalent Population of Interstitial Cystitis in Italy

7.5.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Italy

7.5.3. Total Diagnosed Prevalence of Interstitial Cystitis in Italy

7.5.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy

7.6. Spain

7.6.1. Total Prevalent Population of Interstitial Cystitis in Spain

7.6.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Spain

7.6.3. Total Diagnosed Prevalence of Interstitial Cystitis in Spain

7.6.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain

7.7. United Kingdom

7.7.1. Total Prevalent Population of Interstitial Cystitis in the United Kingdom

7.7.2. Sex-Specific Prevalent Population of Interstitial Cystitis in the United Kingdom

7.7.3. Total Diagnosed Prevalence of Interstitial Cystitis in the United Kingdom

7.7.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom

7.8. Japan

7.8.1. Assumptions and Rationale

7.8.2. Total Prevalent Population of Interstitial Cystitis in Japan

7.8.3. Sex-Specific Prevalent Population of Interstitial Cystitis in Japan

7.8.4. Total Diagnosed Prevalence of Interstitial Cystitis in Japan

7.8.5. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Treatment

8.2. Treatment Algorithm

8.2.1. United States

8.2.2. Japan

8.2.3. Europe

9. Unmet Needs

10. Marketed Drugs

10.1. Elmiron: Janssen Pharmaceutical

10.1.1. Drug Description

10.1.2. Mechanism of action

10.1.3. Regulatory Milestones

10.1.4. Advantages & Disadvantages

10.1.5. Safety and Efficacy

10.1.6. Product Profile

10.2. Instillations

10.3. RIMSO-50: Mylan Pharmaceutical

10.3.1. Drug Description

10.3.2. Mechanism of Action

10.3.3. Regulatory Milestones

10.3.4. Advantages & Disadvantages

10.3.5. Safety and Efficacy

10.3.6. Product Profile

10.4. Cystistat: Bioniche Life Sciences Inc

10.4.1. Drug Description

10.4.2. Mechanism of Action

10.4.3. Regulatory Milestones

10.4.4. Advantages & Disadvantages

10.4.5. Safety and Efficacy

10.4.6. Product Profile

10.5. Gepan instill: Pohl-Boskamp GmbH

10.5.1. Drug Description

10.5.2. Mechanism of Action

10.5.3. Advantages & Disadvantages

10.5.4. Safety and Efficacy

10.5.5. Product Profile

10.6. Uracyst: Stellar Pharmaceuticals

10.6.1. Drug Description

10.6.2. Regulatory Milestones

10.6.3. Advantages & Disadvantages

10.6.4. Safety and Efficacy

10.6.5. Product Profile

10.7. Hyacyst: Syner-Med

10.7.1. Drug Description

10.7.2. Advantages & Disadvantages

10.7.3. Safety and Efficacy

10.7.4. Product Profile

10.8. iAluRil: Aspire Pharma

10.8.1. Drug Description

10.8.2. Mechanism of Action

10.8.3. Advantages & Disadvantages

10.8.4. Safety and Efficacy

10.8.5. Product Profile

11. Emerging Therapies

11.1. Key Cross Competition

11.2. AQX-1125: Aquinox Pharmaceuticals

11.2.1. Product Description

11.2.2. Other Developmental Activities

11.2.3. Clinical Development

11.2.4. Safety and Efficacy

11.2.5. Advantages and Disadvantages

11.2.6. Product Profile

11.3. Mirabegron: Astellas Pharma Global Development

11.3.1. Product Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Development

11.3.4. Safety and Efficacy

11.3.5. Advantages and Disadvantages

11.3.6. Product Profile

11.4. ASP6294: Astellas Pharma Global Development

11.4.1. Product Description

11.4.2. Clinical Development

11.4.3. Product Profile

11.5. LP-08: Lipella Pharmaceuticals

11.5.1. Product Description

11.5.2. Other Developmental Activities

11.5.3. Clinical Development

11.5.4. Safety and Efficacy

11.5.5. Product Profile

11.6. GRT6010: Grünenthal

11.6.1. Product Description

11.6.2. Clinical Development

11.6.3. Product Profile

12. Interstitial Cystitis: 7 Major Market Analysis

12.1. Key Findings

12.2. Market Size of Interstitial Cystitis in 7MM

13. The United States Market Outlook

13.1. United States Market Size

13.2. Total Market size of Interstitial Cystitis in the United States

13.3. Market Size by Current Therapies in the United States

13.4. Market Size by Emerging Therapies in the United States

14. EU-5 Countries: Market Outlook

14.1. Germany

14.1.1. Total Market size of Interstitial Cystitis in Germany

14.1.2. Market Size by Current Therapies in Germany

14.1.3. Market Size by Emerging Therapies in Germany

14.2. France

14.2.1. Total Market size of Interstitial Cystitis in France

14.2.2. Market Size by Current Therapies in France

14.2.3. Market Size by Emerging Therapies in France

14.3. Italy

14.3.1. Total Market size of Interstitial Cystitis in Italy

14.3.2. Market Size by Current Therapies in Italy

14.3.3. Market Size by Emerging Therapies in Italy

14.4. Spain

14.4.1. Total Market Size of Interstitial Cystitis in Spain

14.4.2. Market Size by Current Therapies in Spain

14.4.3. Market Size by Emerging Therapies in Spain

14.5. United Kingdom

14.5.1. Total Market size of Interstitial Cystitis in the United Kingdom

14.5.2. Market Size by Current Therapies in the United Kingdom

14.5.3. Market Size by Emerging Therapies in the United Kingdom

15. Japan: Market Outlook

15.1. Total Market size of Interstitial Cystitis in Japan

15.2. Market Size by Current Therapies in Japan

15.3. Market Size by Emerging Therapies in Japan

16. Market Drivers

17. Market Barriers

18. Appendix

18.1. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Table 1: Potential bladder tissue biomarkers for the diagnosis of IC/BPS

Table 2: Potential urine and serum biomarkers for the diagnosis of IC/BPS

Table 3: Confusable diseases with interstitial cystitis (IC)

Table 4: Recommended tests for diagnosis of interstitial cystitis (IC)

Table 5: Total Prevalent Population of Interstitial Cystitis in the 7MM (2016-2027)

Table 6: Total Diagnosed Prevalent Population of Interstitial Cystitis in the 7MM (2016-2027)

Table 7: Total Prevalent Population of Interstitial Cystitis in the United States (2016-2027)

Table 8: Sex-Specific Prevalent Population of Interstitial Cystitis in the United States (2016-2027)

Table 9: Total Diagnosed Prevalence of Interstitial Cystitis in the United States (2016-2027)

Table 10: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States (2016-2027)

Table 11: Total Prevalent Population of Interstitial Cystitis in Germany (2016-2027)

Table 12: Sex-Specific Prevalent Population of Interstitial Cystitis in Germany (2016-2027)

Table 13: Total Diagnosed Prevalence of Interstitial Cystitis in Germany (2016-2027)

Table 14: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany (2016-2027)

Table 15: Total Prevalent Population of Interstitial Cystitis in France (2016-2027)

Table 16: Sex-Specific Prevalent Population of Interstitial Cystitis in France (2016-2027)

Table 17: Total Diagnosed Prevalence of Interstitial Cystitis in France (2016-2027)

Table 18: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in France (2016-2027)

Table 19: Total Prevalent Population of Interstitial Cystitis in Italy (2016-2027)

Table 20: Sex-Specific Prevalent Population of Interstitial Cystitis in Italy (2016-2027)

Table 21: Total Diagnosed Prevalence of Interstitial Cystitis in Italy (2016-2027)

Table 22: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy (2016-2027)

Table 23: Total Prevalent Population of Interstitial Cystitis in Spain (2016-2027)

Table 24: Sex-Specific Prevalent Population of Interstitial Cystitis in Spain (2016-2027)

Table 25: Total Diagnosed Prevalence of Interstitial Cystitis in Spain (2016-2027)

Table 26: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain (2016-2027)

Table 27: Total Prevalent Population of Interstitial Cystitis in the United Kingdom (2016-2027)

Table 28: Sex-Specific Prevalent Population of Interstitial Cystitis in the United Kingdom (2016-2027)

Table 29: Total Diagnosed Prevalence of Interstitial Cystitis in the United Kingdom (2016-2027)

Table 30: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom (2016-2027)

Table 31: Total Prevalent Population of Interstitial Cystitis in Japan (2016-2027)

Table 32: Sex-Specific Prevalent Population of Interstitial Cystitis in Japan (2016-2027)

Table 33: Total Diagnosed Prevalence of Interstitial Cystitis in Japan (2016-2027)

Table 34: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan (2016-2027)

Figure 35: Interstitial Cystitis Treatments

Table 36: Antidepressants

Table 37: Emerging Drugs Analysis

Table 38: AQX-1125, Clinical Trial Description, 2018

Table 39: AQX-1125, Clinical Trial Description, 2018

Table 40: ASP6294, Clinical Trial Description, 2018

Table 41: LP-08, Clinical Trial Description, 2018

Table 42: GRT6010, Clinical Trial Description, 2018

Table 43: 7 Major Market Size of Interstitial Cystitis in USD Million (2016-2027)

Table 44: United States Market Size of Interstitial Cystitis in USD Million (2016-2027)

Table 45: United States Market Size by current therapies, in USD Million (2016-2027)

Table 46:Market size by emerging therapies in United States, in USD Million (2016-2027)

Table 47: Germany Market Size of Interstitial Cystitis in USD Million (2016-2027)

Table 48: Germany Market Size by current therapies, in USD Million (2016-2027)

Table 49:Market size by emerging therapies in Germany, in USD Million (2016-2027)

Table 50: France Market Size of Interstitial Cystitis in USD Million (2016-2027)

Table 51: France Market Size by current therapies, in USD Million (2016-2027)

Table 52:Market size by emerging therapies in France, in USD Million (2016-2027)

Table 53: Italy Market Size of Interstitial Cystitis in USD Million (2016-2027)

Table 54: Italy Market Size by current therapies, in USD Million (2016-2027)

Table 55:Market size by emerging therapies in Italy, in USD Million (2016-2027)

Table 56: Spain Market Size of Interstitial Cystitis in USD Million (2016-2027)

Table 57: Spain Market Size by current therapies, in USD Million (2016-2027)

Table 58:Market size by emerging therapies in Spain, in USD Million (2016-2027)

Table 59: United Kingdom Market Size of Interstitial Cystitis in USD Million (2016-2027)

Table 60: United Kingdom Market Size by current therapies, in USD Million (2016-2027)

Table 61:Market size by emerging therapies in the United Kingdom, in USD Million (2016-2027)

Table 62: Japan Market Size of Interstitial Cystitis in USD Million (2016-2027)

Table 63: Japan Market Size by current therapies, in USD Million (2016-2027)

Table 64:Market size by emerging therapies in Japan, in USD Million (2016-2027)

Figure 1: Causes of Interstitial Cystitis

Figure 2: Risk Factors for Interstitial Cystitis

Figure 3: Normal bladder transitional epithelium with glycosaminoglycan (GAG) layer covering transitional cells

Figure 4: Pathophysiology for Interstitial Cystitis

Figure 5: Consensus panel recommendations for the evaluation and diagnosis of patients with suspected IC/PBS

Figure 6: Total Prevalent Patient Population of Interstitial Cystitis in the 7MM (2016-2027)

Figure 7: Total Diagnosed Prevalent Patient Population of Interstitial Cystitis in the 7MM (2016-2027)

Figure 8: Total Prevalent Population of Interstitial Cystitis in the United States (2016-2027)

Figure 9: Sex-Specific Prevalent Population of Interstitial Cystitis in the United States (2016-2027)

Figure 10: Total Diagnosed Prevalence of Interstitial Cystitis in the United States (2016-2027)

Figure 11: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States (2016-2027)

Figure 12: Total Prevalent Population of Interstitial Cystitis in Germany (2016-2027)

Figure 13: Sex-Specific Prevalent Population of Interstitial Cystitis in Germany (2016-2027)

Figure 14: Total Diagnosed Prevalence of Interstitial Cystitis in Germany (2016-2027)

Figure 15: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany (2016-2027)

Figure 16: Total Prevalent Population of Interstitial Cystitis in France (2016-2027)

Figure 17: Sex-Specific Prevalent Population of Interstitial Cystitis in France (2016-2027)

Figure 18: Total Diagnosed Prevalence of Interstitial Cystitis in France (2016-2027)

Figure 19: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in France (2016-2027)

Figure 20: Total Prevalent Population of Interstitial Cystitis in Italy (2016-2027)

Figure 21: Sex-Specific Prevalent Population of Interstitial Cystitis in Italy (2016-2027)

Figure 22: Total Diagnosed Prevalence of Interstitial Cystitis in Italy (2016-2027)

Figure 23: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy (2016-2027)

Figure 24: Total Prevalent Population of Interstitial Cystitis in Spain (2016-2027)

Figure 25: Sex-Specific Prevalent Population of Interstitial Cystitis in Spain (2016-2027)

Figure 26: Total Diagnosed Prevalence of Interstitial Cystitis in Spain (2016-2027)

Figure 27: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain (2016-2027)

Figure 28: Total Prevalent Population of Interstitial Cystitis in the United Kingdom (2016-2027)

Figure 29: Sex-Specific Prevalent Population of Interstitial Cystitis in the United Kingdom (2016-2027)

Figure 30: Total Diagnosed Prevalence of Interstitial Cystitis in the United Kingdom (2016-2027)

Figure 31: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom (2016-2027)

Figure 32: Total Prevalent Population of Interstitial Cystitis in Japan (2016-2027)

Figure 33: Sex-Specific Prevalent Population of Interstitial Cystitis in Japan (2016-2027)

Figure 34: Total Diagnosed Prevalence of Interstitial Cystitis in Japan (2016-2027)

Figure 35: Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan (2016-2027)

Figure 36: Sacral nerve stimulator

Figure 37: Treatment Algorithm by American Urology association

Figure 38: Lines of Treatment by American Urology Association

Figure 39: Unmet Needs of Interstitial Cystitis

Figure 40: 7 Major Market Size of Interstitial Cystitis in USD Million (2016-2027)

Figure 41: Market Size of Interstitial Cystitis in the United States, USD Millions (2016-2027)

Figure 42: Market Size by current therapies in the United States, USD Millions (2016-2027)

Figure 43: Market size by emerging therapies in the US, in USD Million (2016-2027)

Figure 44: Market Size of Interstitial Cystitis in Germany, USD Millions (2016-2027)

Figure 45: Market Size by current therapies in Germany, USD Millions (2016-2027)

Figure 46: Market size by emerging therapies in Germany, in USD Million (2016-2027)

Figure 47: Market Size of Interstitial Cystitis in France, USD Millions (2016-2027)

Figure 48: Market Size by current therapies in France, USD Millions (2016-2027)

Figure 49: Market size by emerging therapies in France, in USD Million (2016-2027)

Figure 50: Market Size of Interstitial Cystitis in Italy, USD Millions (2016-2027)

Figure 51: Market Size by current therapies in Italy, USD Millions (2016-2027)

Figure 52: Market size by emerging therapies in Italy, in USD Million (2016-2027)

Figure 53: Market Size of Interstitial Cystitis in Spain, USD Millions (2016-2027)

Figure 54: Market Size by current therapies in Spain, USD Millions (2016-2027)

Figure 55: Market size by emerging therapies in Spain, in USD Million (2016-2027)

Figure 56: Market Size of Interstitial Cystitis in the United Kingdom, USD Millions (2016-2027)

Figure 57: Market Size by current therapies in the United Kingdom, USD Millions (2016-2027)

Figure 58: Market size by emerging therapies in the UK, in USD Million (2016-2027)

Figure 59: Market Size of Interstitial Cystitis in Japan, USD Millions (2016-2027)

Figure 60: Market Size by current therapies in Japan, USD Millions (2016-2027)

Figure 61: Market size by emerging therapies in Japan, in USD Million (2016-2027)

Figure 62: Market Drivers

Figure 63:Market Barriers

  • Tags:
  • Interstitial Cystitis market
  • Interstitial Cystitis market resear...
  • Interstitial Cystitis market insigh...
  • Interstitial Cystitis market trends
  • Interstitial Cystitis market foreca...
  • Interstitial Cystitis market share
  • Interstitial Cystitis pipeline drug...
  • Interstitial Cystitis treatment alg...
  • Interstitial Cystitis drugs
  • Interstitial Cystitis sales forecas...
  • Interstitial Cystitis market size
  • Interstitial Cystitis disease
  • Interstitial Cystitis epidemiology
  • Interstitial Cystitis
  • Interstitial Cystitis Companies
  • Interstitial Cystitis Pipeline

Forward to Friend

Need A Quote